Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The "novel transcript, antisense to ETFA" (ENSG00000287503) is a long non-coding RNA identified in genome annotations as being transcribed from the DNA strand opposite to the ETFA gene, which encodes the alpha subunit of electron transfer flavoprotein, an enzyme critical for mitochondrial fatty acid and amino acid metabolism[2][3][4]. However, this antisense transcript is not annotated as a protein-coding gene nor as a well-characterized regulatory element. There is insufficient evidence to suggest it functions as a therapeutic target or has experimentally validated biological roles, disease associations, or therapeutic significance. Its naming and gene symbol suggest it is best classified as a non-coding RNA of uncertain significance, not as a classical drug target, receptor, enzyme, transporter, or transcription factor.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on novel transcript, antisense to ETFA (ENSG00000287503).